Clostridium Novyi-Nt
Male Reproductive Organ Cancer
Explore 5 assets in Male Reproductive Organ Cancer →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03435952CT.gov Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Male Reproductive Organ Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Clostridium Novyi-Nt (this asset) | M.D. Anderson Cancer Center | P1 | CC · 43 |
| Daratumumab | M.D. Anderson Cancer Center | P2 | CCC |
| Cyclophosphamide | M.D. Anderson Cancer Center | P1 | CC |
| Cord Blood-Derived Expanded Allogeneic Natural Killer Cells | M.D. Anderson Cancer Center | P1 | CC |
| Olaparib | M.D. Anderson Cancer Center | P1 | CC |
| Doxycycline | M.D. Anderson Cancer Center | P1 | CC |
| Etoposide | M.D. Anderson Cancer Center | P1 | CC |
| Lenvatinib | M.D. Anderson Cancer Center | P1 | CC |
| Temsirolimus | M.D. Anderson Cancer Center | P1 | CC |
+5 more in the Male Reproductive Organ Cancer cohort
Other indications for Clostridium Novyi-Nt
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Digestive System Cancer | — | P1 | CC · 43 |
| Female Reproductive Organ Cancer | — | P1 | CC · 43 |
| Breast Cancer | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Clostridium Novyi-Nt in Male Reproductive Organ Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/clostridium-novyi-nt-male-reproductive-organ-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →